Related Experiment Video
Updated: Sep 21, 2025
10:58
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
17.2K
Design of D-Amino Acids SARS-CoV-2 Main Protease Inhibitors Using the Cationic Peptide from Rattlesnake Venom as a
Raphael J Eberle1,2, Ian Gering1, Markus Tusche1
1Institute of Biological Information Processing (IBI-7: Structural Biochemistry), Forschungszentrum Jülich, 52428 Jülich, Germany.
Pharmaceuticals (Basel, Switzerland)
|May 28, 2022
Summary
D-enantiomer peptides derived from crotamine show promise in combating severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). These D-peptides effectively inhibit the viral 3C-like protease (3CLpro) and reduce viral replication in vivo.
Area of Science:
- Biochemistry
- Virology
- Drug Discovery
Background:
- The 3C-like protease (3CLpro) of SARS-CoV-2 is crucial for viral replication and a key drug target.
- Crotamine, a peptide from rattlesnake venom, has diverse biological activities.
- L-peptide derivatives of crotamine (L-CDP) inhibit 3CLpro but are prone to degradation.
Purpose of the Study:
- To investigate the potential of D-enantiomer crotamine derivatives (D-CDP) as SARS-CoV-2 inhibitors.
- To evaluate D-CDP as a stable alternative to L-CDP for antiviral drug development.
Main Methods:
- Synthesis and characterization of D-enantiomer crotamine derivatives (D-CDP).
- Comparative analysis of uptake inhibition for L-CDP and D-CDP.
- In vivo assessment of D-CDP's efficacy against SARS-CoV-2 replication.
Main Results:
- D-CDP demonstrated significant inhibition of the SARS-CoV-2 3CLpro.
- Comparative uptake studies identified D-CDP as a promising prototype for D-peptide drugs.
- D-peptides were found to impair SARS-CoV-2 replication in vivo.
Conclusions:
- D-enantiomer crotamine derivatives represent a viable strategy for developing novel SARS-CoV-2 therapeutics.
- D-peptides offer enhanced stability and potential for targeting the viral 3CLpro.
- Further development of D-CDP could lead to effective treatments for SARS-CoV-2 infection.
